BioSuperior develops novel therapeutics targeting chronic lung conditions such as COPD and pulmonary fibrosis, using proprietary biologic platforms to modulate disease pathways. Their pipeline includes inhaled and systemic candidates designed to improve lung function and reduce exacerbations, aiming to address unmet needs in respiratory care.
Funding
$256K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic lung diseases such as COPD and pulmonary fibrosis have limited treatment options that effectively halt disease progression, improve lung function, or reduce the frequency of acute exacerbations, leaving many patients with persistent symptoms and declining quality of life.
Solution
BioSuperior leverages proprietary biologic platforms to create novel therapeutics that modulate key disease pathways in the lung. The company’s pipeline includes both inhaled and systemic candidates designed to directly target the underlying mechanisms of chronic lung conditions, aiming to improve pulmonary function and decrease exacerbation rates. By partnering with leading academic centers, BioSuperior conducts rigorous clinical trials to assess safety and efficacy, accelerating the translation of its biologic approaches into viable treatment options for patients with unmet respiratory needs.
Target Audience
Primary customers are pharmaceutical partners, academic research groups, and healthcare providers seeking advanced therapies for patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Features
- Proprietary biologic discovery platform focused on lung‑specific disease pathways
- Dual delivery modalities (inhaled and systemic) to optimize drug exposure in the respiratory tract
- Candidates engineered to reduce inflammation, fibrosis, and tissue remodeling in COPD and pulmonary fibrosis
- Collaborative clinical development program with top academic research institutions
- Integrated biomarker strategy to monitor target engagement and therapeutic response